TR BioSurgical To Present New Glaucoma Device Data At ACVO

CHANDLER, Ariz. – (September 24th, 2008)   TR BioSurgical, LLC has been selected to present data concerning their proprietary glaucoma device, TR-ClarifEYE, at the American College of Veterinary Ophthalmologist’s (ACVO) annual conference. Glaucoma affects a large percentage of dogs and has devastating consequences including pain and blindness. TR-ClarifEYE, made of a unique biomaterial, proposes to offer improved biocompatibility compared to current products and provide a much needed long-term solution for thousands of dogs each year which develop glaucoma.             Dr. Craig Woods, CEO of TR BioSurgical, LLC, stated, “We are excited to present our interim data at this year’s veterinary ophthalmology meeting. Our team has developed a device with remarkable properties to enhance tissue integration and long term performance. We are very encouraged by the results and intend on establishing a limited global treatment network in the coming months, providing veterinarians access to the implant.” About Canine Glaucoma Glaucoma is one of the most common causes of blindness in dogs and humans. Glaucoma is associated with an increase in pressure within the eye, referred to as intraocular pressure (IOP). Increased IOP causes pain and damage to sensitive tissues within the eye, resulting in a progressive loss of vision. Despite a number of surgical and medical options, canine glaucoma is still considered a disease with limited long term management options. About TR ClarifEYE TR ClarifEYE is a medical device consisting of medical grade silicone substrate that has been converted into the Sphere Templated Angiogenic Regeneration (STAR) Material by Healionics Corporation. This unique process creates a precise pore structure that enhances healing and reduces fibrosis, an effect that proposes to permit long term filtration. About TR BioSurgical, LLC: TR BioSurgical, LLC, founded in May 2007, is a rapidly growing veterinary biomedical development company located in Chandler, Arizona. The company was founded by veterinarians and business professionals and is developing a range of medical devices for veterinary use. For more information about TR BioSurgical, please visit http://www.trbio.com About Healionics Corporation Healionics is a privately held biomaterials company whose mission is to be the leading provider of tissue regeneration and device biointegration solutions to healthcare manufacturers. Their flagship STAR - Sphere Templated Angiogenic Regeneration – biomaterial scaffold is a next generation solution for improving the performance of implanted medical devices. Healionics Corporation is headquartered in Redmond, Washington. For more information, please visit http://www.healionics.com

More from

• IVC Evidensia assembles expert team to run new £10m referral hospital
• Home delivery service can increase pet health plan sign-ups by 25%
• Research reveals vital clues to help fight anthelmintic resistance
• Lifetime Achievement Award recognises Harrogate vet’s dedication to improving the health and welfare of rabbits
• Bake sale at Leicestershire vet practice for good cause